 <h1>Raniclor Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>cefaclor</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about cefaclor. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Raniclor.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cefaclor: oral capsules, oral extended-release tablets, oral for suspension</i></p><p>Side effects include:</p><p>Diarrhea, genital pruritus or vaginitis, headache, nausea, vomiting, rash.          </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cefaclor: oral capsule, oral powder for reconstitution, oral tablet chewable, oral tablet extended release</i></p><h3>General</h3><p>ER TABLETS: The most commonly reported side effects included headache, rhinitis, diarrhea, and nausea.</p><p></p><p>IR CAPSULES: The most commonly reported side effects included abdominal pain, diarrhea, morbilliform eruptions, and hypersensitivity reactions.</p><p></p><p>CR/MR TABLETS: The most commonly reported side effects included headache, diarrhea, nausea, and vaginal moniliasis.</p><p></p><p>ORAL SUSPENSION: The most commonly reported side effects included diarrhea and hypersensitivity reactions.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>ER TABLETS:</p><p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, nausea</p><p><b>Uncommon</b> (0.1% to 1%): Constipation, dyspepsia, flatulence, gastritis, nausea and vomiting, vomiting</p><p><b>Postmarketing reports</b>: Pseudomembranous colitis symptoms</p><p></p><p>IR CAPSULES:</p><p><b>Common</b> (1% to 10%): Diarrhea</p><p><b>Rare</b> (0.01% to 0.1%): Nausea, vomiting</p><p><b>Frequency not reported</b>: Abdominal pain, colitis, pseudomembranous colitis</p><p></p><p>CR/MR TABLETS:</p><p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, nausea</p><p><b>Frequency not reported</b>: Colitis, dyspepsia, pseudomembranous colitis, vomiting</p><p></p><p>ORAL SUSPENSION:</p><p><b>Common</b> (1% to 10%): Diarrhea, gastrointestinal symptoms</p><p><b>Rare</b> (0.01% to 0.1%): Colitis, pseudomembranous colitis, nausea, vomiting</p><p><b>Frequency not reported</b>: Abdominal pain<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>ER TABLETS:</p><p><b>Common</b> (1% to 10%): Pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Maculopapular rash, rash, sweating, urticaria</p><p><b>Frequency not reported</b>: Erythema multiforme</p><p><b>Postmarketing reports</b>: Face edema, Stevens-Johnson syndrome, toxic epidermal necrolysis</p><p></p><p>IR CAPSULES:</p><p><b>Common</b> (1% to 10%): Morbilliform eruption</p><p><b>Very rare</b> (less than 0.01%): Pruritus, urticaria</p><p><b>Frequency not reported</b>: Erythema multiforme, face edema, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p><p></p><p>CR/MR TABLETS:</p><p><b>Common</b> (1% to 10%): Pruritus, rash, urticaria</p><p><b>Frequency not reported</b>: Erythema multiforme, erythema multiforme minor, face edema, morbilliform eruptions, Stevens-Johnson syndrome, toxic epidermal necrolysis</p><p></p><p>ORAL SUSPENSION:</p><p><b>Common</b> (1% to 10%): Morbilliform eruptions</p><p><b>Uncommon</b> (0.1% to 1%): Erythema multiforme, pruritus, rash, urticaria</p><p><b>Rare</b> (0.01% to 0.1%): Erythema multiforme major, Stevens-Johnson syndrome, toxic epidermal necrolysis</p><p><b>Frequency not reported</b>: Erythema multiforme minor, face edema<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>ER TABLETS:</p><p><b>Common</b> (1% to 10%): Vaginal moniliasis, vaginitis</p><p><b>Uncommon</b> (0.1% to 1%): Dysmenorrhea, dysuria, leukorrhea, menstrual disorder, nocturia</p><p><b>Postmarketing reports</b>: Abnormal urinalysis, genital pruritus</p><p></p><p>IR CAPSULES:</p><p><b>Frequency not reported</b>: Abnormal urinalysis, false positive test for urinary glucose, genital pruritus, vaginal moniliasis, vaginitis</p><p></p><p>CR/MR TABLETS:</p><p><b>Common</b> (1% to 10%): Vaginal moniliasis, vaginitis</p><p><b>Frequency not reported</b>: Abnormal urinalysis, genital pruritus, hematuria, proteinuria, pyuria</p><p></p><p>ORAL SUSPENSION:</p><p><b>Frequency not reported</b>: Abnormal urinalysis, false positive test for urinary glucose, genital pruritus, hematuria, proteinuria, pyuria, vaginal moniliasis, vaginitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p>ER TABLETS:</p><p><b>Common</b> (1% to 10%): Cough increased, pharyngitis, rhinitis</p><p><b>Uncommon</b> (0.1% to 1%): Asthma, bronchitis, lung disorder, respiratory disorder, sinusitis</p><p></p><p>IR CAPSULES:</p><p><b>Frequency not reported</b>: Dyspnea</p><p></p><p>CR/MR TABLETS:</p><p><b>Common</b> (1% to 10%): Epistaxis</p><p><b>Frequency not reported</b>: Dyspnea</p><p></p><p>ORAL SUSPENSION:</p><p><b>Frequency not reported</b>: Dyspnea<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Anaphylaxis may occur more frequently in patients with a history of penicillin allergy.</p><p></p><p>Hypersensitivity reaction symptoms may persist for several months.</p><p></p><p>Serum-sickness-like reactions were more frequently reported in pediatric patients and after a second/subsequent course of treatment; reactions have been characterized by arthritis/arthralgia, erythema multiforme, and rash with or without fever.<sup>[Ref]</sup></p><p>ER TABLETS:</p><p><b>Uncommon</b> (0.1% to 1%): Serum sickness-like reaction</p><p><b>Frequency not reported</b>: Hypersensitivity reactions, severe hypersensitivity reactions</p><p><b>Postmarketing reports</b>: Allergic reaction, anaphylactoid events, anaphylaxis, angioedema</p><p></p><p>IR CAPSULES:</p><p><b>Common</b> (1% to 10%): Hypersensitivity reactions</p><p><b>Uncommon</b> (0.1% to 1%): Serum sickness-like reaction</p><p><b>Frequency not reported</b>: Anaphylactoid events, anaphylaxis, angioedema, severe hypersensitivity reactions</p><p></p><p>CR/MR TABLETS:</p><p><b>Rare</b> (0.01% to 0.1%): Serum sickness-like reaction</p><p><b>Frequency not reported</b>: Allergic reactions, anaphylactoid events, anaphylaxis, angioedema, severe hypersensitivity reactions</p><p></p><p>ORAL SUSPENSION:</p><p><b>Common</b> (1% to 10%): Hypersensitivity reactions</p><p><b>Uncommon</b> (0.1% to 1%): Serum sickness-like reactions</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis, angioedema</p><p><b>Frequency not reported</b>: Anaphylactoid events<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>ER TABLETS:</p><p><b>Common</b> (1% to 10%): Back pain</p><p><b>Uncommon</b> (0.1% to 1%): Arthralgia, creatine phosphokinase increased, myalgia, neck pain, somnolence</p><p><b>Frequency not reported</b>: Arthritis</p><p></p><p>IR CAPSULES:</p><p><b>Frequency not reported</b>: Arthralgia, arthritis</p><p></p><p>CR/MR TABLETS:</p><p><b>Frequency not reported</b>: Arthralgia, arthritis</p><p></p><p>ORAL SUSPENSION:</p><p><b>Frequency not reported</b>: Arthralgia, arthritis<sup>[Ref]</sup></p><h3>Nervous system</h3><p>ER TABLETS:</p><p><b>Common</b> (1% to 10%): Headache</p><p><b>Uncommon</b> (0.1% to 1%): Dizziness, somnolence, tremor</p><p><b>Postmarketing reports</b>: Hypertonia, paresthesia, reversible hyperactivity, syncope, vertigo</p><p></p><p>IR CAPSULES:</p><p><b>Rare</b> (0.01% to 0.1%): Dizziness, hypertonia, reversible hyperactivity, somnolence</p><p><b>Frequency not reported</b>: Paresthesia, seizures, syncope</p><p></p><p>CR/MR TABLETS:</p><p><b>Common</b> (1% to 10%): Headache</p><p><b>Frequency not reported</b>: Dizziness, hypertonia, paresthesia, reversible hyperactivity, seizures, somnolence, syncope</p><p></p><p>ORAL SUSPENSION:</p><p><b>Rare</b> (0.01% to 0.1%): Dizziness, hypertonia, reversible hyperactivity, somnolence</p><p><b>Frequency not reported</b>: Paresthesia, seizures, syncope<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Increased prothrombin time with/without clinical bleeding was reported in patients given IR capsules and warfarin concurrently.</p><p></p><p>Transient fluctuations in leukocyte count most commonly occurred in infants and young children.<sup>[Ref]</sup></p><p>ER TABLETS:</p><p><b>Uncommon</b> (0.1% to 1%): Eosinophils increased, erythrocyte count decreased, hemoglobin decreased, lymphocytes decreased, mean cell volume (MCV) increased, neutrophils segmented decreased, platelet count decreased</p><p><b>Postmarketing reports</b>: Eosinophilia, hemolytic anemia, leukopenia, neutropenia, positive direct Coombs test, transient thrombocytopenia</p><p></p><p>IR CAPSULES:</p><p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis, aplastic anemia, hemolytic anemia, reversible neutropenia (may be of clinical significance), thrombocytopenia</p><p><b>Very rare</b> (less than 0.01%): Positive Coombs test</p><p><b>Frequency not reported</b>: Eosinophilia, pancytopenia, transient leukopenia, transient lymphocytosis</p><p><b>Postmarketing reports</b>: Increased prothrombin time with/without clinical bleeding</p><p></p><p>CR/MR TABLETS:</p><p><b>Frequency not reported</b>: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, increased prothrombin time with/without clinical bleeding, leukopenia, lymphadenopathy, lymphocytosis, neutropenia (may be of clinical significance), positive direct Coombs test, transient fluctuations in leukocyte count, transient thrombocytopenia</p><p></p><p>ORAL SUSPENSION:</p><p><b>Uncommon</b> (0.1% to 1%): Positive Coombs test</p><p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis, aplastic anemia, hemolytic anemia, reversible neutropenia (may be of clinical significance), thrombocytosis, thrombocytopenia</p><p><b>Frequency not reported</b>: Eosinophilia, leukopenia, lymphadenopathy, pancytopenia, transient fluctuations in leukocyte count, transient lymphocytosis</p><p><b>Postmarketing reports</b>: Increased prothrombin time with/without clinical bleeding<sup>[Ref]</sup></p><h3>Other</h3><p>ER TABLETS:</p><p><b>Uncommon</b> (0.1% to 1%): Accidental injury, chills, ear pain, fever, malaise, otitis media, pain, surgical procedure</p><p></p><p>IR CAPSULES:</p><p><b>Frequency not reported</b>: Asthenia, fever</p><p></p><p>CR/MR TABLETS:</p><p><b>Common</b> (1% to 10%): Asthenia, pain</p><p><b>Frequency not reported</b>: Fever</p><p></p><p>ORAL SUSPENSION:</p><p><b>Rare</b> (0.01% to 0.1%): Fever</p><p><b>Frequency not reported</b>: Asthenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p>ER TABLETS:</p><p><b>Uncommon</b> (0.1% to 1%): Albumin decreased, anorexia, calcium increased, phosphorus increased, potassium increased, sodium decreased/increased<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>EXTENDED RELEASE (ER) TABLETS:</p><p><b>Uncommon</b> (0.1% to 1%): Chest pain, congestive heart failure, edema, palpitation, peripheral edema</p><p><b>Postmarketing reports</b>: Hypotension, limb edema, vasodilation</p><p></p><p>IMMEDIATE RELEASE (IR) CAPSULES:</p><p><b>Frequency not reported</b>: Hemorrhage, hypotension, limb edema, vasodilation</p><p></p><p>MODIFIED RELEASE (CR/MR) TABLETS:</p><p><b>Frequency not reported</b>: Limb edema, vasodilation</p><p></p><p>ORAL SUSPENSION:</p><p><b>Frequency not reported</b>: Hemorrhage, hypotension, limb edema, vasodilation<sup>[Ref]</sup></p><h3>Hepatic</h3><p>ER TABLETS:</p><p><b>Uncommon</b> (0.1% to 1%): Alkaline phosphatase increased, ALT increased, GGT increased, total bilirubin increased</p><p><b>Postmarketing reports</b>: Cholestasis, liver dysfunction, transient AST elevation</p><p></p><p>IR CAPSULES:</p><p><b>Rare</b> (0.01% to 0.1%): Cholestatic jaundice, transient hepatitis</p><p><b>Frequency not reported</b>: Elevated bilirubin, elevated LDH, slight alkaline phosphatase elevations, slight ALT elevations, slight AST elevations</p><p></p><p>CR/MR TABLETS:</p><p><b>Frequency not reported</b>: Cholestasis, cholestatic jaundice, liver dysfunction, transient alkaline phosphatase elevations, transient ALT elevations, transient AST elevations, transient hepatitis</p><p></p><p>ORAL SUSPENSION:</p><p><b>Rare</b> (0.01% to 0.1%): Cholestatic jaundice, liver dysfunction, transient hepatitis</p><p><b>Frequency not reported</b>: Elevated bilirubin, elevated LDH, slight alkaline phosphatase elevations, slight ALT elevations, slight AST elevations<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>ER TABLETS:</p><p><b>Uncommon</b> (0.1% to 1%): Anxiety, insomnia, nervousness</p><p><b>Postmarketing reports</b>: Confusion</p><p></p><p>IR CAPSULES:</p><p><b>Rare</b> (0.01% to 0.1%): Agitation, confusion, hallucinations, insomnia, nervousness</p><p></p><p>CR/MR TABLETS:</p><p><b>Frequency not reported</b>: Agitation, confusion, hallucinations, insomnia, nervousness</p><p></p><p>ORAL SUSPENSION:</p><p><b>Rare</b> (0.01% to 0.1%): Agitation, confusion, hallucinations, insomnia, nervousness<sup>[Ref]</sup></p><h3>Renal</h3><p>ER TABLETS:</p><p><b>Uncommon</b> (0.1% to 1%): Blood urea nitrogen (BUN) increased, creatinine increased</p><p><b>Postmarketing reports</b>: Reversible interstitial nephritis</p><p></p><p>IR CAPSULES:</p><p><b>Rare</b> (0.01% to 0.1%): Reversible interstitial nephritis</p><p><b>Frequency not reported</b>: Renal dysfunction, slight BUN elevations, slight serum creatinine elevations, toxic nephropathy</p><p></p><p>CR/MR TABLETS:</p><p><b>Frequency not reported</b>: Renal dysfunction, reversible interstitial nephritis, toxic nephropathy, transient serum creatinine increase, transient serum urea/BUN increase</p><p></p><p>ORAL SUSPENSION:</p><p><b>Rare</b> (0.01% to 0.1%): Reversible interstitial nephritis</p><p><b>Frequency not reported</b>: Renal dysfunction, slight elevation in serum creatinine, slight elevation in serum urea/BUN, toxic nephropathy<sup>[Ref]</sup></p><h3>Ocular</h3><p>ER TABLETS:</p><p><b>Uncommon</b> (0.1% to 1%): Conjunctivitis<sup>[Ref]</sup></p><h3>Immunologic</h3><p>ER TABLETS:</p><p><b>Uncommon</b> (0.1% to 1%): Flu syndrome, infection</p><p></p><p>IR CAPSULES:</p><p><b>Frequency not reported</b>: Moniliasis, superinfection</p><p></p><p>CR/MR TABLETS:</p><p><b>Frequency not reported</b>: Moniliasis</p><p></p><p>ORAL SUSPENSION:</p><p><b>Frequency not reported</b>: Moniliasis, superinfection<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals, San Diego, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company, Indianapolis, IN. </p><h2>More about Raniclor (cefaclor)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Drug class: second generation cephalosporins</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bladder Infection</li>
<li>Bronchitis</li>
<li>Kidney Infections</li>
<li>Otitis Media</li>
<li data-more-config-id="list-data-resources-conditions">... +7 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>